Korenberg Matthew E 4
4 · PALVELLA THERAPEUTICS, INC. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
PALVELLA (PVLA) CFO Matthew Korenberg Receives 44,123-Share Option Award
What Happened
- Matthew E. Korenberg, Chief Financial Officer and Treasurer of Palvella Therapeutics (PVLA), received a grant of 44,123 derivative shares/options on Feb 5, 2026. The grant was recorded at $0.00 at acquisition (no cash paid at grant). This is an equity award (derivative) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-05; Form 4 filed: 2026-02-09 (filed within the SEC two-business-day window).
- Award: 44,123 shares (derivative/options) acquired at $0.00.
- Vesting: The award vests and becomes exercisable in equal monthly installments over 48 months beginning Feb 5, 2026 (≈ 918 shares vest per month).
- Shares owned after the transaction: Not provided in the supplied filing summary.
- Filing code: A = Grant/Award; no 10b5-1 plan, tax withholding, or cashless-sale details reported in the provided data.
Context
- This was a granted option/award, not an open-market purchase or immediate sale; no immediate cash changed hands. Such grants are a routine form of executive compensation and vest over time to align incentives with company performance and retention.
Insider Transaction Report
Form 4
Korenberg Matthew E
CFO, Treasurer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-02-05+44,123→ 44,123 totalExercise: $76.43Exp: 2036-02-05→ Common Stock (44,123 underlying)
Footnotes (1)
- [F1]The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Kathleen A. McGowan, Attorney-in-Fact|2026-02-09